Lifastuzumab vedotin

Lifastuzumab vedotin
Monoclonal antibody
Type?
SourceHumanized (from mouse)
Targetphosphate-sodium cotransporter
Clinical data
Other namesDNIB0600A
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6504H10028N1744O2018S46
Molar mass146416.72 g·mol−1

Lifastuzumab vedotin (INN;[1] development code DNIB0600A) is an experimental monoclonal antibody-drug conjugate designed for the treatment of cancer.[2]

This drug was developed by Genentech/Roche.

References

  1. ^ World Health Organization (2013). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 110" (PDF). WHO Drug Information. 27 (4).
  2. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Lifastuzumab Vedotin, American Medical Association.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.